Fig. 2From: Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trialGeometric mean and 95% CI of specific antibody responses (AUC) to A S1, B RBD, and C neutralizing antibody titer in the BBIBP-CorV and RCP groups over the predefined study time schedule. Error bars are 95% CIsBack to article page